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Abstract
Background: The guidelines recommend that first line treatment of chronic spontaneous urticaria should be second
generation non-sedating H1-antihistamines with a positive recommendation against the use of old sedating first generation
antihistamines. If standard dosing is not effective, increasing the dosage up to four-fold is recommended. The objective of
this study was to obtain the chronic spontaneous urticaria-patient perspective on the effectiveness and unwanted effects of
H1-antihistamines in standard and higher doses.
Methodology/Principal Findings: This was a questionnaire based survey, initially completed by 368 individuals. 319 (248
female, 71 male, median age 42 years) had a physician-confirmed diagnosis of chronic spontaneous urticaria and were
included in the results. Participants believed standard doses (manufacturers recommended dose) of second generation
antihistamines to be significantly (P,0.005) more effective than first generation drugs. Furthermore, they believed that
second generation drugs caused significantly (P,0.001) fewer unwanted effects and caused significantly (P,0.001) less
sedation than first generation antihistamines. Three-quarters of the patients stated that they had up-dosed with
antihistamines with 40%, 42% and 54% reporting significant added benefit from taking 2, 3 or 4 tablets daily respectively.
The number of reports of unwanted effects and sedation following up-dosing were not significantly different from those
reported for standard doses.
Conclusions: This survey supports the urticaria guidelines recommendations that the first line treatment for chronic
spontaneous urticaria should be second generation rather than first generation H1-antihistamines and that, if standard
dosing is not effective, the dosage should be increased up to four-fold.
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Introduction
Chronicurticaria,definedasurticariawithepisodesextendingfor
morethan 6 weeks [1],is a relatively commonconditionfromwhich
0.5–1% of the population suffers at any single time [2] with all age
groups and social strata affected. Furthermore, epidemiological
studies haveshown that this condition, whichmaylastformonthsor
even years [3,4] may lead to major detrimental effects on quality of
life, sleep deprivation and be associated with mental illness [5–7].As
a consequence, effective therapy is of paramount importance.
The guidelines issued following the third international consen-
sus meeting on urticaria in 2008, a joint initiative of the
Dermatology Section of the European Academy of Allergology
and Clinical Immunology (EAACI), the EU-funded network of
excellence, the Global Allergy and Asthma European Network
(GA
2LEN), the European Dermatology Forum (EDF) and the
World Allergy Organization (WAO) [8], recommended that the
first line treatment for chronic urticaria should be second
generation, non-sedating H1-antihistamines. There is a positive
recommendation against the routine use of old sedating first
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increasing the dosage of non-sedating H1-antihistamines up to
four-fold is recommended. Only if patients do not respond to this
four-fold increase in dosage it is recommended that second-line
therapies should be added to the antihistamine treatment. While
many dermatologists use up-dosing regularly, the justification for it
is based on long-standing clinical experience rather than good
scientific evidence. It is only more recently that clinical trials have
been performed to assess the response of H1-antihistamines at two
times [9–12], three times [13,14] and four times [15,16] the
licensed dose. However, what still remains to be done is to assess
how patients view up-dosing with H1-antihistamines.
In this study, we have used a questionnaire to ask 319 patients
with chronic spontaneous urticaria about the course of their
condition, their previous treatment and its effectiveness with a
special focus on their experience with up-dosing with H1-
antihistamines. The results demonstrate that the patients rate
second generation antihistamines to be more effective and better
tolerated than first generation drugs and that many patients
benefit from increasing the dose up to fourfold in case the standard
licensed dose is not capable to adequately control their symptoms.
Methods
Objectives
The main objective of this study was to assess the effectiveness
and side effects of sedating vs. non-sedating H1-antihistamines as
well as of non-sedating H1-antihistamines in standard vs. higher
than standard doses from the patients’ perspective.
Procedures and Participants
This was a questionnaire based retrospective survey initially
completed by 368 individuals of whom 319 had a positive
diagnosis of chronic spontaneous urticaria and were included in
the results. Of these, 121 received questionnaires from their
hospital or physician and 198 learnt about the survey on the
internet from either the homepage of Allergie-Centrum-Charite ´o r
the web page of the Urticaria Network e.V. (www.urtikaria.net).
The latter group completed the questionnaire online. Both
physician administered and on-line questionnaires were identical.
All questionnaires were completed anonymously and no Internet
Protocol (IP) addresses were saved. Individuals from all 16 Federal
States of Germany, 36% from rural areas, 38% from urban areas
and 26% from metropolitan areas participated in the study. The
only prerequisite for participation was that the individuals suffered
from chronic spontaneous urticaria (recurrent spontaneous occur-
ing wheals for .6 weeks) and were adults of age 18 or older. In
addition, all participants were asked, if their urticaria was
diagnosed by a physician (response options ‘‘yes’’ and ‘‘no’’).
Only those subjects who responded with ‘‘yes’’ were included in
the analysis.
Ethics
All participants received a patient information sheet before
participation. To assure the full anonymity of the data set formal
written informed consent was not obtained. However, the patient
information contained a passage informing the participants that
they declare their consent by completing the questionnaire. The
survey and the indirect method of obtaining patient consent were
both approved by the ethics committee (Ethikkommission der
Charite ´ - Universita ¨tsmedizin Berlin, EA1/200/09) and the data
protection commissioner of the Charite ´ – Universita ¨tsmedizin,
Berlin.
Data and Statistics
The data collected by this retrospective patient survey included
the following: epidemiology and method of securing of the
diagnosis, details of previous and current therapy, reasons for
changing therapies, and experience with up-dosing with H1-
antihistamines. In total, the questionnaire consisted of 54
questions, mostly involving Likert-scale ratings, quantitative
questions, yes/no lists and multiple choice questions (the
questionnaire can be provided upon request). The questions were
assigned to the following subheadings: 1) general information (on
the participants), 2) questions concerning the symptoms and course
of disease, 3) questions concerning the diagnosis of urticaria, 4)
questions concerning the treatment of urticaria, 5) questions
concerning the impact of urticaria and 6) questions regarding care
and the physician patient relationship. For the questions relevant
to this manuscript, no time frame was specified in order to obtain
as much patient experience as possible. Differences between first
and second generation H1-antihistamines and standard and high
dose therapy were tested using Fishers exact test.
Results
Patient details
The 319 respondents included in the survey (248 female and 71
male) of median age 42 years (range 18 to 76 years) stated that
they had symptoms consistent with chronic spontaneous urticaria
and had their diagnosis confirmed by a physician. Of the
physicians who confirmed the diagnosis, 70% were dermatologists.
The mean duration of the respondents’ urticaria since diagnosis
was 7066 months (mean 6 SEM) with wheals occurring daily in
48% of patients and several times a month in 95% of patients.
Individual wheals lasted less than 24 hours in 87% of patients. Of
the respondents, 25% rated their symptoms as moderate-to-severe,
46% as severe and 25% rated them as very severe. Furthermore,
68% reported that they also had symptoms of angioedema and
71% could not identify a cause for urticaria.
Spectrum of H1-antihistamines used
The patients in the survey stated that they had taken at least one
of twelve H1-antihistamines from a given list, of which four,
clemastine, dimethindene, hydroxyzine and promethazine, were
first generation ‘sedating’ antihistamines and eight, cetirizine,
desloratadine, ebastine, fexofenadine, levocetirizine, loratadine,
mizolastine, rupatadine, were second generation, ‘non-sedating’
antihistamines (Figure 1).
Altogether, 205 respondents reported a total of 322 changes
from one antihistamine to another during progression of their
disease. The reason for changing medication was stated 230 times
to be due to lack of effectiveness and 87 times due to side effects.
First versus second generation H1-antihistamines
The patients’ perspective of the comparative efficacy of first and
second generation H1-antihistamines taken at the standard dose
(manufacturers recommended or licensed dose) is shown in
Figure 2. For statistical comparisons, the responses were divided
into twogroups;significant improvement orcomplete freedom from
symptoms and slight or no improvement. The results (Table 1)
show that the patients believed second generation antihistamines to
be significantly (P,0.005)more effective than first generation drugs.
The patients were also asked whether or not taking a standard
dose of H1-antihistamines caused unwanted effects. The responses
(Table 1) showed first generation antihistamines to cause
significantly (P,0.001) more unwanted effects than second
generation drugs. Furthermore, more respondents stated that they
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with second generation drugs. Again, the difference was highly
significant (P,0.001).
Up-dosing with H1-antihistamines
A total of 238 of the 319 patients (75%) in the survey stated that
they had increased their daily dose of antihistamine to two, three
or four tablets daily. Of these, 216 (68%) of the patients stated that
they had taken this course of action because of the lack of
effectiveness when taking a standard dose. Figure 3 shows the
effectiveness of up-dosing with second generation H1-antihista-
mines. Of the reports from individuals who had stated that they
had up-dosed, 40%, 42% and 54% showed significant added
benefit from taking 2, 3 or 4 tablets daily rather than standard dose
therapy while approximately one quarter stated that no additional
benefit had been derived.
Unwanted effects and concerns with up-dosing
The number of reports of unwanted effects and sedation
following up-dosing with second generation H1-antihistamines are
shown in Table 2 and are not statistically different from those
reported for the use of standard doses of antihistamines. However,
of the 135 reports about unwanted effects, 85 gave also
information on the magnitude at high doses in comparison to
regular doses of the same second generation H1-antihistamine: 30
(35%) stated that the unwanted effects were considerably worse
and 33 (39%) stated that they were somewhat worse.
Patients also expressed concerns about up-dosing with H1-
antihistamines. Of the 319 respondents, 26% were worried about
possible side effects, 23% about possible long term harmful effects,
19% about the possible loss of efficacy, 9% about becoming
dependent on their medication and 3% about other unspecified
effects.
Discussion
This survey shows that, from a patients’ perspective, a standard
licensed dose of an H1-antihistamine often fails to provide
adequate symptomatic relief in chronic spontaneous urticaria.
This is evidenced by the reported 322 changes of medication and
the finding that 75% of the respondents reported to increasing
their daily dose of antihistamines in order to improve symptomatic
control.
Because this survey asked questions relating to treatment over
many years, many patients stated that they either had been or are
being treated with first generation H1-antihistamines. These drugs,
many of which have been available for more than 50 years, have
pronounced anticholinergic effects and central nervous system
sedative actions which limit the doses at which they can be given
[17,18]. Consequently, in clinical usage for urticaria, first
generation H1-antihistamines are generally less effective than
second generation drugs [19], a conclusion supported by our
survey. Furthermore, it is well established that taking first
generation H1-antihistamines in standard doses frequently leads
to side effects of which daytime somnolence, sedation, drowsiness,
fatigue and impaired concentration and memory are the most
prominent [17,20,21]. The finding in this survey that first
generation H1-antihistamines were associated with significantly
more side effects and sedation than second generation drugs
supports these conclusions. These results support the recommen-
dation in the guidelines [8] that the first line treatment for chronic
urticaria should be second generation H1-antihistamines rather
than the old sedating first generation H1-antihistamines.
Of the responses from patients taking second generation
antihistamines, 23% stated that the feeling of sedation was a
problem. This is considerably higher than somnolence levels cited
in clinical studies [20–22]. However, the majority of sedation
studies with H1-antihistamines are performed in either healthy
individuals or individuals with mild disease rather than in
conditions, such as severe chronic urticaria, in which sleep
disturbances are a major issue [23]. Thus, in surveys such as
Figure 1. The spectrum of H1-antihistamines taken by the
patients for the treatment of their chronic spontaneous
urticaria. The results are expressed as the total number of participants
who reported information on the efficacy of the itemized antihista-
mines in regular dose.
doi:10.1371/journal.pone.0023931.g001
Figure 2. The comparative efficacy first and second generation
H1-antihistamines in chronic spontaneous urticaria. The histo-
grams were constructed from 147 and 721 patient reports respectively.
doi:10.1371/journal.pone.0023931.g002
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reported by the patients is due to the drug and what is due to their
condition.
Of the reports from individuals who had stated that they had
up-dosed their H1-antihistamine, approximately half stated that
there was a significant benefit compared with standard dose
therapy while approximately one quarter stated that no additional
benefit had been derived. This finding that in many cases of
chronic spontaneous urticaria, therapy with H1-antihistamines is
not sufficient, even at higher than licensed doses, confirms
previous studies [2,11,16].
Perhaps the major concern shared by both patients and doctors
concerns the possibility of somnolence with up-dosing of H1-
antihistamines. However, in this survey, the percentage of reports
of sedation following up-dosing compared with standard doses of
H1-antihistamines was not statistically different. There are two
possible reasons for this. The first is that the relief from urticaria-
related discomfort led to a better quality of sleep with subsequent
less sedation during the day [16]. The second possibility, which is
likely to occur in parallel, is the development of tolerance to the
central nervous sedative effects of the antihistamines which occurs
with prolonged periods of administration [24,25].
However, of the reports received following antihistamine up-
dosing, many stated that unwanted effects were worse than with
the standard dose. This illustrates the patient variability to the
central nervous effects of second generation H1-antihistamines and
that the blanket term of ‘non-sedating’ for this class of drug is not
appropriate for many patients.
Strengths and limitations of this study
The major strengths of this study are: first, that it canvassed the
opinions of patients from many walks of life from all over
Germany; second, patients were only admitted after a physician
had confirmed the diagnosis of chronic spontaneous urticaria;
many patients had taken both first and second generation
antihistamines and were, therefore, able to compare their efficacy
and unwanted effects; and, fourth, three quarters of the patients
had up-dosed with antihistamines. The weaknesses of the study
are: first, many patients commented on drugs that they had taken
many years ago and, therefore, their memory of relevant details
may be a little unreliable (recall bias); second, because of the size of
the cohort, co-morbidities could not be included in the analysis;
and, third, due to the way of patient recruitment, a selection effect
can not be excluded.
Conclusions
In conclusion, this survey has shown that approximately three
quarters of reports indicate that patients obtain additional
benefit from up-dosing with H1-antihistamines. Also, in
approximately three quarters of responses, the reported
frequency of side effects was no greater than with standard
doses. Furthermore, the survey shows a clear benefit of second
generation over first generation drugs in both efficacy and their
side effects. These results, therefore, support the guidelines
recommendations [8] that the first line treatment for chronic
spontaneous urticaria should be second generation H1-antihis-
tamines and that, if standard dosing is not effective, the dosage
should be increased up to four-fold.
Table 1. Comparison of first and second generation H1-antihistamines in chronic spontaneous urticaria.
First generation Second generation Significance of Difference
Effectiveness:
Significant or total improvement 15.6% 26.8%
Slight or no improvement 84.4% 73.2% P,0.005
(n=147) (n=721)
Unwanted Effects:
Unwanted Effects 46.5% 31.6% P,0.001
Sedation 38.9% 22.7% P,0.001
(n=157) (n=699)
The first generation ‘sedating’ antihistamines were clemastine, dimethindene, hydroxyzine and promethazine and the second generation, ‘non-sedating’ antihistamines
were cetirizine, desloratadine, ebastine, fexofenadine, levocetirizine, loratadine, mizolastine and rupatadine. All were taken at the standard licensed dose. Statistical
comparisons were made using Fisher’s exact test. n indicates the number of reports received for each condition.
doi:10.1371/journal.pone.0023931.t001
Figure 3. Effectiveness of H1-antihistamine updosing in chronic
spontaneous urticaria. The reported effectiveness of up-dosing with
second generation H1-antihistamines compared with standard dose
therapy in chronic spontaneous urticaria. The number of patient reports
in each group are; 2 tablets=108, 3 tablets=72 and 4 tablets=85.
doi:10.1371/journal.pone.0023931.g003
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